Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from GlaxoSmithKline

Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.

Evening Standard

Screeching U-turn as Unilever’s shareholders balk at £50bn GSK deal

Riot in ranks sends ‘strong message’ against tilt at GlaxoSmithKline’s consumer division

The Guardian - UK

Unilever CEO Alan Jope serves up ‘red meat’ with buyback and pledge not to do big deals

Under-pressure Unilever CEO Alan Jope today tried to placate restless investors with “red meat” offerings as he tries to move on from a botched bid for GlaxoSmithKline’s consumer healthcare business.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

GlaxoSmithKline: Q4 Earnings Insights

GlaxoSmithKline (NYSE:GSK) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Under pressure GlaxoSmithKline promises ‘landmark’ year as its outshone by Pfizer

GlaxoSmithKline remained under pressure today after so-so results that drew unfavourable comparisons with US rival Pfizer.

Evening Standard

GSK claims $1.2bn victory in HIV patent battle with US rival Gilead

Drugmaker GlaxoSmithKline today claimed a landmark victory in its competitive battle to dominate HIV treatment as a US rival agreed to hand over $1.25 billion to end a high-stakes global patent dispute.

Evening Standard

Why the London Stock Exchange has become a playground for activist investors

GlaxoSmithKline, SSE, Unilever, and Shell have all found themselves in the crosshairs of activist funds who until recently focused their attentions on Wall Street — why?

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Marmite and Dove maker Unilever to cut 1,500 jobs in huge global restructuring

Unilever products include Domestos bleach, Ben & Jerry's ice cream and Hellman’s mayonnaise. The announcement comes after it lost a takeover bid for GlaxoSmithKline - the maker of Aquafresh toothpaste and Panadol

Daily Mirror

Unilever’s doomed £50bn GlaxoSmithKline bid was a ‘near-death experience’

Fund manager Terry Smith made a fresh attack on Unilever following the collapse of its bid for GlaxoSmithKline’s consumer-health unit, saying the Dove soap maker needs to focus more on fixing its own business.

Evening Standard

Unilever won't up £50bn offer for GSK-Pfizer unit

LONDON: Consumer goods giant Unilever on Wednesday said it would not increase a £50-billion offer for the consumer healthcare unit owned by pharmaceutical groups GlaxoSmithKline and Pfizer.

Bangkok Post

Unilever won't top $68B bid for GSK consumer healthcare unit

Unilever, the maker of Vaseline skin care products and Dove soap, says it won’t increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline’s consumer healthcare unit that was rejected last week

The Independent UK

Unilever vows not to increase GSK bid

Unilever has effectively ruled out a fourth takeover approach for GlaxoSmithKline’s consumer healthcare business after vowing not to increase its offer.

Evening Standard

Unilever punished by City for failed £50bn tilt at GSK

A PROPOSED fire-sale of under-performing food assets failed to stem the blood-letting at Unilever today as the City issued a damning verdict over its failed £50 billion tilt at GlaxoSmithKline.

Evening Standard

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.